Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity
Abstract
Neuropilin 2 (NRP2) expression in tissue is an independent prognostic factor for aggressive prostate cancer. Since the NRP2 pathway activation is thought to occur in part through secondary resistance, quantification of NRP2 in initial tissue biopsy specimens collected at diagnosis may have limited utility in identifying patients at highest risk for morbidity and mortality. Given that metastatic tissue is only occasionally obtained for analysis, there is a need for development of a plasma biomarker indicative of NRP2 pathway activation to potentially inform prostate cancer prognosis. Therefore, we investigated if plasma levels of NRP2 or vascular endothelial growth factor C (VEGF‐C), a known soluble ligand of NRP2, are prognostic for prostate cancer. We hypothesized that plasma NRP2 and VEGF‐C would be associated with more advanced disease or relapsed disease.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 09, 2023
- Source ID
- 10.1002/pros.24648
Entities
People
- Benjamin A Teply
- Dipanwita Das
- Kaustubh Datta
- Negin Ziamiavaghi
- Robin High
- Sarah A. Mullen
Organizations
- National Institutes of Health
- United States Department of Defense
- University of Nebraska Medical Center
- University of Nebraska–Lincoln